62 related articles for article (PubMed ID: 11220893)
1. [Poseidonol in the treatment of patients with hyperlipidemia].
Panchenko VM; Isaev VA; Nalukhanian SO; Ershov AA; Zimovchenko GS
Klin Med (Mosk); 2000; 78(10):20-2. PubMed ID: 11220893
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness and tolerability of simvastatin plus fenofibrate for combined hyperlipidemia (the SAFARI trial).
Grundy SM; Vega GL; Yuan Z; Battisti WP; Brady WE; Palmisano J
Am J Cardiol; 2005 Feb; 95(4):462-8. PubMed ID: 15695129
[TBL] [Abstract][Full Text] [Related]
3. Effect of combination nicotinic acid and gemfibrozil treatment on intermediate density lipoprotein, and subclasses of low density lipoprotein and high density lipoprotein in patients with combined hyperlipidemia.
Superko HR; Garrett BC; King SB; Momary KM; Chronos NA; Wood PD
Am J Cardiol; 2009 Feb; 103(3):387-92. PubMed ID: 19166694
[TBL] [Abstract][Full Text] [Related]
4. [Poseidonol in the treatment of hyperlipidemia in patients with type 2 diabetes mellitus].
Panchenko VM; Ershov AA; Isaev VA; ZImovchenko GS; Chernova GI
Klin Med (Mosk); 2001; 79(6):47-9. PubMed ID: 11521381
[TBL] [Abstract][Full Text] [Related]
5. Safety and efficacy of long-term co-administration of fenofibrate and ezetimibe in patients with mixed hyperlipidemia.
McKenney JM; Farnier M; Lo KW; Bays HE; Perevozkaya I; Carlson G; Davies MJ; Mitchel YB; Gumbiner B
J Am Coll Cardiol; 2006 Apr; 47(8):1584-7. PubMed ID: 16630994
[TBL] [Abstract][Full Text] [Related]
6. The effect of ciprofibrate on flow-mediated dilation and inflammatory markers in patients with combined hyperlipidemia.
Kovács I; Toldy E; Abel T; Tarján J; Császár A
Endothelium; 2005; 12(4):179-83. PubMed ID: 16162440
[TBL] [Abstract][Full Text] [Related]
7. [Familial combined hyperlipidemia].
de Bruin TW; Dallinga-Thie GM; Erkelens DW
Ned Tijdschr Geneeskd; 1996 Oct; 140(43):2118-21. PubMed ID: 8965962
[No Abstract] [Full Text] [Related]
8. [Long-term treatment of hyperlipoproteinemia with etofibrate].
Bartz VT; Gatz J; Slotty C; Schröter C; Töle R; Wand P
Fortschr Med; 1993 Sep; 111(25):398-400. PubMed ID: 8406286
[TBL] [Abstract][Full Text] [Related]
9. The effect of apolipoprotein E polymorphism on the response to lipid-lowering treatment with atorvastatin or fenofibrate.
Christidis DS; Liberopoulos EN; Kakafika AI; Miltiadous GA; Cariolou M; Ganotakis ES; Mikhailidis DP; Elisaf MS
J Cardiovasc Pharmacol Ther; 2006 Sep; 11(3):211-21. PubMed ID: 17056835
[TBL] [Abstract][Full Text] [Related]
10. Comparison of fluvastatin + fenofibrate combination therapy and fluvastatin monotherapy in the treatment of combined hyperlipidemia, type 2 diabetes mellitus, and coronary heart disease: a 12-month, randomized, double-blind, controlled trial.
Derosa G; Cicero AE; Bertone G; Piccinni MN; Ciccarelli L; Roggeri DE
Clin Ther; 2004 Oct; 26(10):1599-607. PubMed ID: 15598476
[TBL] [Abstract][Full Text] [Related]
11. Atorvastatin monotherapy vs. combination therapy in the management of patients with combined hyperlipidemia.
Avisar I; Brook JG; Wolfovitz E
Eur J Intern Med; 2008 May; 19(3):203-8. PubMed ID: 18395165
[TBL] [Abstract][Full Text] [Related]
12. The effect of fenofibrate on serum paraoxonase activity and inflammatory markers in patients with combined hyperlipidemia.
Yesilbursa D; Serdar A; Saltan Y; Serdar Z; Heper Y; Guclu S; Cordan J
Kardiol Pol; 2005 Jun; 62(6):526-30. PubMed ID: 16123850
[TBL] [Abstract][Full Text] [Related]
13. Effect of statins on LDL particle size in patients with familial combined hyperlipidemia: a comparison between atorvastatin and pravastatin.
Sirtori CR; Calabresi L; Pisciotta L; Cattin L; Pauciullo P; Montagnani M; Manzato E; Bittolo Bon G; Fellin R
Nutr Metab Cardiovasc Dis; 2005 Feb; 15(1):47-55. PubMed ID: 15871851
[TBL] [Abstract][Full Text] [Related]
14. Decreased circulating Fas ligand in patients with familial combined hyperlipidemia or carotid atherosclerosis: normalization by atorvastatin.
Blanco-Colio LM; Martín-Ventura JL; Sol JM; Díaz C; Hernández G; Egido J
J Am Coll Cardiol; 2004 Apr; 43(7):1188-94. PubMed ID: 15063428
[TBL] [Abstract][Full Text] [Related]
15. [Long-term administration of tyquanol in the treatment of patients with ischemic heart disease in combination with hyperlipidemia].
Panchenko VM; Ershov AA; Isaev VA
Klin Med (Mosk); 2003; 81(3):40-2. PubMed ID: 12698850
[TBL] [Abstract][Full Text] [Related]
16. Treatment of type IIb familial combined hyperlipidemia with the combination pravastatin-piperazine sultosilate.
Masana L; Villoria J; Sust M; Ros E; Plana N; Pérez-Jiménez F; Franco M; Oliván JJ; Pintó X; Videla S
Eur J Pharmacol; 2004 Aug; 496(1-3):205-12. PubMed ID: 15288592
[TBL] [Abstract][Full Text] [Related]
17. Comparison of combined statin-fibrate treatment to monotherapy in patients with mixed hyperlipidemia.
Kłosiewicz-Latoszek L; Szostak WB; Grzybowska B; Białobrzeska-Paluszkiewicz J; Wiśniewska B; Stolarska I
Kardiol Pol; 2004 Jun; 60(6):567-77. PubMed ID: 15334157
[TBL] [Abstract][Full Text] [Related]
18. Increased plasma levels of oxysterols, in vivo markers of oxidative stress, in patients with familial combined hyperlipidemia: reduction during atorvastatin and fenofibrate therapy.
Arca M; Natoli S; Micheletta F; Riggi S; Di Angelantonio E; Montali A; Antonini TM; Antonini R; Diczfalusy U; Iuliano L
Free Radic Biol Med; 2007 Mar; 42(5):698-705. PubMed ID: 17291993
[TBL] [Abstract][Full Text] [Related]
19. Qualitative effect of fenofibrate and quantitative effect of atorvastatin on LDL profile in combined hyperlipidemia with dense LDL.
Winkler K; Weltzien P; Friedrich I; Schmitz H; Nickell HH; Hauck P; Hoffmann MM; Baumstark MW; Wieland H; März W
Exp Clin Endocrinol Diabetes; 2004 May; 112(5):241-7. PubMed ID: 15146369
[TBL] [Abstract][Full Text] [Related]
20. Normal lipid metabolism, familial hyperlipidaemia, lipid intervention and their benefits.
Koner BC; Goswami K; Kavitha S; Moorthy RS
J Indian Med Assoc; 2003 Feb; 101(2):89-92. PubMed ID: 12841490
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
